Superior Planning, LLC’s Spyre Therapeutics SYRE Stock Holding History

Superior Planning, LLC’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12K	Buy	+135	New	+$13K	0.01%	865

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Superior Planning, LLC's SYRE Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Spyre Therapeutics (SYRE) in Q3 2026: 135 shares worth $12K. The stake represents 0.01% of the portfolio and ranks #865 among its holdings.

155 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.

Superior Planning, LLC held 135 shares of Spyre Therapeutics worth $12K as of Q3 2026.
Spyre Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Spyre Therapeutics made up 0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #865 holding.
155 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.